Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and tolerability of eculizumab in multifocal motor neuropathy
2008-005748-18Phase 2Completed
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Dec 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eculizumab in multifocal motor neuropathy (MMN), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Frequency of adverse events and serious adverse events. Started Dec 2008; status: completed.
02
Drugs
eculizumab
03
Conditions
multifocal motor neuropathy (MMN)
Beyond the preview
Go deeper on 2008-005748-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005748-18.